| 证券代码 | TAHT.O |
| 证券名称 | SynCardia Systems Inc |
| 证券类型 | 美股 |
| 上市场所 | 纳斯达克交易所 |
| 上市板块 | - |
| 发行方式 | - |
| 首发上市日 | - |
| 首发价格(元) | - |
| 首发数量(股) | 0 |
| 首发募资额(元) | - |
| 首发主承销商 | - |
| 货币单位 | USD |
| 公司名称 | SynCardia Systems, Inc. |
| 注册地址 | 美国特拉华州 |
| 办公地址 | 1992 East Silverlake Road, Tucson, Arizona, USA |
| 成立日期 | 2001-08 |
| 董事会主席 | - |
| 公司属地 | United States 美国 |
| 公司网址 | www.syncardia.com |
| 电话 | +1 (520) 545-1234 |
| 传真 | - |
| 公司简介 | SynCardia Systems, Inc. is a medical technology company focused on developing, manufacturing and commercializing the SynCardia temporary Total Artificial Heart, or TAH-t, an implantable system designed to assume the full function of a failed human heart in patients suffering from advanced heart failure. The SynCardia TAH-t is the only total artificial heart that is commercially available in the United States, European Union and Canada for use as a bridge to heart transplantation. As a total artificial heart, the SynCardia TAH-t replaces the functionality of both the left and right ventricles of the heart as well as all four heart valves. In combination with an external driver that delivers precisely calibrated pulses of air, the SynCardia TAH-t provides blood flow of up to 9.5 liters per minute through each ventricle, lowering central venous pressure and promoting the recovery of other vital organs. They require each medical center to be trained and certified in the implantation of the SynCardia TAH-t and appropriate patient aftercare before they will sell their device to the center. They refer to centers that have successfully completed these certification programs as “SynCardia Certified Centers.” |